scholarly journals Central Corneal Thickness Measurements in Nonarteritic Anterior Ischemic Optic Neuropathy Patients: A Controlled Study

2014 ◽  
Vol 2014 ◽  
pp. 1-3 ◽  
Author(s):  
Haneen Jabaly-Habib ◽  
Modi Naftali ◽  
George Habib
Keyword(s):  
Optic Neuropathy ◽  
Central Corneal Thickness ◽  
Corneal Thickness ◽  
Anterior Ischemic Optic Neuropathy ◽  
Controlled Study ◽  
Control Group ◽  
Ischemic Optic Neuropathy ◽  
History Of ◽  
Group 2 ◽  
Group 1

Purpose. To measure central corneal thickness (CCT) in patients with history of nonarteritic anterior ischemic optic neuropathy (NAION).Patients and Methods. Patients older than 40 years with a history of NAION (group 1) were prospectively evaluated including full eye examination and central corneal thickness (CCT) pachymetry. Patients with a history of intraocular surgery, corneal disease, glaucoma, and contact lens wear were excluded. Measurements were also performed in a gender and age matched control group (group 2).Results. Thirty-one eyes of 31 NAION patients in group 1 were included and 30 eyes of 30 participants in group 2. There were 15 men in group 1 and 9 in group 2P=0.141, and mean age of the patients was59±10years in group 1 versus61±11years in group 2P=0.708. Mean CCT was539±30microns in group 1 and550±33microns in group 2P=0.155.Conclusion. Patients with NAION have no special characteristic of CCT in contrast to the crowded optic disc known to be a significant anatomic risk factor for NAION. More studies should be carried out to investigate CCT and other structure related elements in NAION patients.

scholarly journals Evaluation of enhanced external counterpulsation therapy for nonarteritic anterior ischemic optic neuropathy

2020 ◽  
Author(s):  
Lixia Lin ◽  
Wenhui Zhu ◽  
Nan Ma ◽  
Xiaofeng Lin ◽  
Hui Yang
Keyword(s):  
Optic Neuropathy ◽  
Visual Function ◽  
Anterior Ischemic Optic Neuropathy ◽  
Controlled Study ◽  
Control Group ◽  
Ischemic Optic Neuropathy ◽  
External Counterpulsation ◽  
Significant Difference ◽  
And Control ◽  
Enhanced External Counterpulsation

Abstract Background To explore the effects of enhanced external counterpulsation (EECP) and its underlying influencing factors in nonarteritic anterior ischemic optic neuropathy (NAION) patients. Methods Patients at Zhongshan Ophthalmic Center with recent-onset (<8 weeks) NAION were retrospectively recruited. The patients had decided whether or not they would undergo EECP treatment, and the patients who declined were included in the control group. The effectiveness of EECP was evaluated by comparing the visual function and fellow eye involvement in patients with and without EECP treatment. Results In total, 61 patients (76 eyes) were included. Twenty-nine patients (37 eyes) underwent EECP treatment, while 32 patients (39 eyes) were included in the control group. Mean time from NAION onset to EECP initiation was 27.59±16.70 days. In the EECP group, the mean EECP duration was 31.57±18.45 days. EECP was well tolerated by all patients. However, there was no significant difference in visual function between the EECP and control groups, regardless of time to treatment initiation. Furthermore, there was no evidence of the effectiveness of EECP in the subgroup analysis of patients with different systemic health conditions. Among the 42 patients with monocular NAION, the sequential attack rate was comparable between the EECP (27.78%) and control (25.00%) groups. Conclusion This study is the first nonrandomized controlled study to evaluate the effectiveness of EECP in NAION patients. Unfortunately, we failed to demonstrate the effectiveness of EECP in NAION at the 6-month follow-up. Any further application of EECP in NAION patients should be cautious.

scholarly journals Evaluation of enhanced external counterpulsation therapy for nonarteritic anterior ischemic optic neuropathy

2020 ◽  
Author(s):  
Lixia Lin ◽  
Wenhui Zhu ◽  
Nan Ma ◽  
Xiaofeng Lin ◽  
Hui Yang
Keyword(s):  
Optic Neuropathy ◽  
Visual Function ◽  
Anterior Ischemic Optic Neuropathy ◽  
Controlled Study ◽  
Control Group ◽  
Ischemic Optic Neuropathy ◽  
External Counterpulsation ◽  
Significant Difference ◽  
And Control ◽  
Enhanced External Counterpulsation

Abstract Background To explore the effects of enhanced external counterpulsation (EECP) and its underlying influencing factors in nonarteritic anterior ischemic optic neuropathy (NAION) patients. Methods Patients at Zhongshan Ophthalmic Center with recent-onset (<8 weeks) NAION were retrospectively recruited. The patients had decided whether or not they would undergo EECP treatment, and the patients who declined were included in the control group. The effectiveness of EECP was evaluated by comparing the visual function and fellow eye involvement in patients with and without EECP treatment. Results In total, 61 patients (76 eyes) were included. Twenty-nine patients (37 eyes) underwent EECP treatment, while 32 patients (39 eyes) were included in the control group. Mean time from NAION onset to EECP initiation was 27.59±16.70 days. In the EECP group, the mean EECP duration was 31.57±18.45 days. EECP was well tolerated by all patients. However, there was no significant difference in visual function between the EECP and control groups, regardless of time to treatment initiation. Furthermore, there was no evidence of the effectiveness of EECP in the subgroup analysis of patients with different systemic health conditions. Among the 42 patients with monocular NAION, the sequential attack rate was comparable between the EECP (27.78%) and control (25.00%) groups. Conclusion This study is the first nonrandomized controlled study to evaluate the effectiveness of EECP in NAION patients. Unfortunately, we failed to demonstrate the effectiveness of EECP in NAION at the 6-month follow-up. Any further application of EECP in NAION patients should be cautious.

scholarly journals Effect of anterior capsular polishing on the incidence of YAG capsulotomy

2016 ◽  
Vol 11 (3) ◽  
Author(s):  
Muhammad A Ahad ◽  
Mohammad Rashad Qamar ◽  
Sameh K Hindi ◽  
Martin N Kid
Keyword(s):  
Outcome Measure ◽  
Early Postoperative Period ◽  
Controlled Study ◽  
Control Group ◽  
Anterior Capsule ◽  
Main Outcome Measure ◽  
Group I ◽  
Group 2 ◽  
One Year ◽  
Group 1

Purpose: To study the effect of anterior capsule polishing during phacoemulsification on the incidence of post operative YAG laser capsulotomy. Method: A retrospective controlled study of 159 patients who underwent uncomplicated phacoemulsification with anterior capsular polishing between October 1998 and March 2000. 169 age matched patients who underwent phacoemulsification but without anterior capsule polishing served as controls. Main outcome measure: Incidence of visually significant YAG capsulotomy, which improved the Snellen acuity for more than 1 line or at least 1 line with subjective improvements in symptoms. Results: 2.51 % of patients with anterior capsular polishing (Group 1) had YAG capsulotomy compared to 7.1% of patients in control group at one year. However, after two years, 11.3% of patients in Group I had YAG capsulotomy compared to 12.4% in Group 2. Conclusion: Anterior capsular polishing during cataract surgery may delay the opacification of posterior capsule during the early postoperative period. But does not decrease the incidence of YAG capsulotomy after two years.

scholarly journals Effect of Acute Increases in Intraocular Pressure on Corneal Pachymetry in Rabbit Eyes Treated with Timolol Maleate

2018 ◽  
Vol 12 (1) ◽  
pp. 314-321
Author(s):  
Cristina Sánchez-Barahona ◽  
Gema Bolívar ◽  
Dimitrios G. Mikropoulos ◽  
Anastasios G. Konstas ◽  
Miguel A. Teus
Keyword(s):  
Intraocular Pressure ◽  
Anterior Chamber ◽  
Central Corneal Thickness ◽  
Corneal Thickness ◽  
Rabbit Model ◽  
Controlled Study ◽  
Control Group ◽  
Study Group ◽  
Timolol Maleate

Objective: To evaluate in an in vivo rabbit model, the effect of topical timolol maleate therapy on the central corneal thickness response to acute intraocular pressure increases. Method: In this prospective and interventional controlled study, the central corneal thickness and intraocular pressure were measured in vivo in 12 rabbit eyes treated with topical timolol maleate for 1 month and in 12 controls at baseline, and after the intraocular pressure (measured by direct cannulation of the anterior chamber) was increased to 15 and 30 mmHg using a forced saline infusion into the anterior chamber. Results: There were no significant differences in the basal central corneal thickness values (control group, 373.2±12.9 µm; study group, 377.5±19.2 µm, p=0.5) or the central corneal thickness values when the intraocular pressure was increased to 15 mmHg (control group, 335.2±14.3 µm; study group, 330.0±32.1 µm, p=0.6) and to 30 mmHg (study group, 318.8±25.3 µm; control group, 329.8±21.0 µm, p=0.3). Conclusion: Rabbit corneas treated with topical timolol maleate for 1 month did not show a strain response to acute intraocular pressure increases that differed from control eyes. This is in contrast to a previous finding in which rabbit eyes treated with prostaglandin analogues had a greater decrease in central corneal thickness in response to a sudden intraocular pressure increase compared with untreated corneas.

Dysregulatory visceropathies in patients with uterine endometriosis and recurrent endometrial hyperplasia

1986 ◽  
Vol 67 (5) ◽  
pp. 347-349
Author(s):  
N. I. Petrushkova
Keyword(s):  
Endometrial Hyperplasia ◽  
Digestive System ◽  
Practical Significance ◽  
Control Group ◽  
Liver And Pancreas ◽  
Rational Therapy ◽  
History Of ◽  
Group 2 ◽  
Digestive Glands ◽  
Group 1

The study of neurohormonal-visceral relationships in patients with uterine endometriosis is of practical significance in the development of rational therapy and prevention of this complex and rather frequent pathology. This study was aimed to investigate the functional state of the digestive glands of the stomach, intestines, liver and pancreas in 152 patients with uterine internal endometriosis (Group 1) and in 50 patients with recurrent endometrial hyperplasia (Group 2). Twenty healthy women were the control group. Patients with no history of diseases of the digestive system were selected for the examination.

Psychiatric Morbidity in Sentenced Segregated HIV-Positive Prisoners

1993 ◽  
Vol 163 (6) ◽  
pp. 802-805 ◽  
Author(s):  
Arthur Dorman ◽  
Art O'Connor ◽  
Eamonn Hardiman ◽  
Aideen Freyne ◽  
Helen O'Neill
Keyword(s):  
Drug Abuse ◽  
Matched Control ◽  
Psychiatric Morbidity ◽  
Hiv Positive ◽  
Control Group ◽  
Matched Control Group ◽  
History Of ◽  
The Mean ◽  
Group 2 ◽  
Group 1

In this comparative study with a control group of prisoners, psychiatric morbidity was measured in two groups of sentenced prisoners, each group completing the GHQ-30 and 21-item Beck Depression Inventory (BDI). Group 1 consisted of 40 segregated HIV-positive prisoners and group 2 a matched control group in the main prison who had no history of HIV seropositivity. All members of group 1 had a history of intravenous drug abuse. The mean GHQ-30 and BDI scores were significantly higher in group 1, and 90% of group 1 were psychiatric ‘cases’ compared with just over 42% of group 2. Levels of psychiatric morbidity present in a third group, consisting of HIV-positive prisoners who had not been segregated (prison authorities were unaware of their seropositivity) are an interesting pointer for further research.

scholarly journals Fluoxetine for Anterior Ischemic Optic Neuropathy (AION); a Double Blind Randomized Clinical Trial

2021 ◽  
Author(s):  
Mohammad Hossein Abbasi ◽  
Shahnaz Rimaz ◽  
Zahra Pourmousa ◽  
Leila Janani ◽  
Mostafa Soltan Sanjari
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Optic Neuropathy ◽  
Study Groups ◽  
Anterior Ischemic Optic Neuropathy ◽  
Control Group ◽  
Ischemic Optic Neuropathy ◽  
Double Blind ◽  
Clinical Prognosis ◽  
Before And After

Abstract Background: Fluoxetine enhances the levels of brain-derived neurotrophic factor (BDNF); considering its known improving effects on neurogenesis and plasticity, it seems to improve the Anterior Ischemic Optic Neuropathy (AION). This study aimed to evaluate the effect of Fluoxetine on clinical prognosis of patients with AION.Methods: In this double-blind placebo-controlled randomized clinical trial, subjects with AION who were referred to Rasool Akram Hospital were divided into two study groups; the fluoxetine group that received 20 mg Fluoxetine daily(n=50) and the control group (n=50) that received placebo for a period of six months. Patients underwent clinical and paraclinical evaluations before and after the trial. This study was a registered trial with IRCT code IRCT20181109041596N1.Results: One hundred patients were enrolled from August 2019 to December 2020 and assessed in this study. Subjects in Fluoxetine group showed significant improvement in visual acuity in comparison to the placebo group with less score in LogMAR scale (P: 0.008 and 0.002, respectively), improvement in MD parameters of perimetry (P: 0.003 and 0.002, respectively), and decrease in VEP latencies (P (in 1st minute): <0.001 and <0.001, P (in 15st minute): 0.038 and 0.011, respectively). There were no differences in color vision, Rnfl in all dimensions, PSD parameter of perimetry or VEP amplitudes following the trial of Fluoxetine therapy (Ps> 0.05).Conclusion: Fluoxetine showed promising therapeutic value for patients with AION besides its safety as an additive treatment option to corticosteroids.

Sign in / Sign up

Export Citation Format

Share Document